Pancragen (Lys-Glu-Asp-Trp) is a synthetic tetrapeptide developed by Vladimir Khavinson’s bioregulatory peptide research group. It is classified as a pancreatic bioregulator, with preclinical studies examining its effects on insulin-producing beta cells and glucose metabolism. Published data comes almost exclusively from Russian-language sources, with no controlled human trials in Western peer-reviewed literature.

📖 Read the full Pancragen research overview →

Evidence Tier: Tier 4 — Preclinical Only · Peptidings Verdict: Eyes Open